{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:29:11Z","timestamp":1767979751958,"version":"3.49.0"},"reference-count":115,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriatic disease is a multifaceted disorder, which develops in the skin, its appendages and joints. Though characterized by different pathogenic background and clinical manifestations, skin plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>) are related, sharing key inflammatory mechanisms and hence mode of management. Secukinumab is a fully human monoclonal antibody that selectively binds and neutralizes interleukin\u201017A. It has been approved for use as a subcutaneous injection for the treatment of moderate\u2010to\u2010severe PsO, PsA and <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>. The current review highlights the long\u2010term efficacy and safety profile of secukinumab in the treatment of plaque psoriasis and its multiple manifestations from its phase 3 clinical trial programme. The long\u2010term extension of pivotal trials has shown sustainable efficacy and safety of secukinumab up to 5\u00a0years in PsO, PsA and <jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content> and up to 2.5\u00a0years in moderate\u2010to\u2010severe nail and palmoplantar PsO through dedicated randomized controlled trials. The effect of secukinumab therapy in all these indications has corresponding effects on improvement in quality\u2010of\u2010life and daily activities. Overall, secukinumab is an effective and safe treatment choice for patients suffering from psoriatic disease in its multiple clinical variants.<\/jats:p>","DOI":"10.1111\/jdv.16124","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T10:29:57Z","timestamp":1575282597000},"page":"1161-1173","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Long\u2010term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease"],"prefix":"10.1111","volume":"34","author":[{"given":"K.","family":"Reich","sequence":"first","affiliation":[{"name":"Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf Hamburg Germany"},{"name":"Skinflammation\u00ae Center Hamburg Germany"},{"name":"Dermatologikum Berlin Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre Manchester Academic Health Science Centre The University of Manchester Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.C.","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Di Comite","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,7]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201804030"},{"key":"e_1_2_6_4_1","first-page":"145","article-title":"Psoriasis increases the risk of concurrent inflammatory bowel disease: a population\u2010based nationwide study in Korea","volume":"85","author":"Lee JY","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.07.029"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.10.026"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.72455"},{"key":"e_1_2_6_8_1","first-page":"923","article-title":"Evidence\u2010based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult\u2010to\u2010treat sites (nails, scalp, palms, and soles)","volume":"105","author":"Sanchez\u2010Regana M","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589"},{"key":"e_1_2_6_10_1","first-page":"S7","article-title":"Nail psoriasis","volume":"33","author":"Manhart R","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1610-0387.2010.07412.x","article-title":"Scalp psoriasis","volume":"9","author":"Wozel G","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0191-y"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329502"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2014.914437"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12437"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15177"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12024"},{"key":"e_1_2_6_20_1","first-page":"10","article-title":"Current guidelines for psoriasis treatment: a work in progress","volume":"101","author":"Golbari NM","year":"2018","journal-title":"Cutis"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12110"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12359"},{"key":"e_1_2_6_24_1","first-page":"S12","article-title":"Secukinumab in the treatment of palmoplantar, nail, scalp, and pustular psoriasis","volume":"9","author":"Armstrong AW","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12751"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13236"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.008"},{"key":"e_1_2_6_30_1","unstructured":"BlauveltA ReichK TsaiTFet\u00a0al.Continuous Treatment with Secukinumab 300\u00a0mg Demonstrates Sustained Efficacy in Clearing Skin and Improving Patient\u2010Reported Outcomes in Moderate to Severe Plaque Psoriasis: Two Year Results From the CLEAR Study. In:26th European Academy of Dermatology and Venereology Congress.Geneva Switzerland.2017."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.011"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"},{"key":"e_1_2_6_33_1","unstructured":"RichardLangley BS JacekS Tsen\u2010FangTet\u00a0al.Secukinumab is Associated with Sustained Improvement in Patients\u2019 Quality of Life up to Year 5: Results of a Randomized Extension of the Phase III ERASURE and FIXTURE Trials. In:6th congress of the SPIN \u2013 Skin Inflammation & Psoriasis International Network.Paris France.2019."},{"key":"e_1_2_6_34_1","unstructured":"PappK GooderhamM AlaviAet\u00a0al.Secukinumab Treatment Results in Improvement of Disease Characteristics in Patients with Moderate to Severe Psoriasis: 24 Month Follow\u2010up Data from the PURE Registry. In:2019 AAD Annual Meeting. Washington DC. March 1\u20105 2019; Poster #10084."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.062"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1528000"},{"key":"e_1_2_6_37_1","unstructured":"YanofskyH SiddhaS AdamDet\u00a0al.Secukinumab demonstrates significant improvement of disease activity and health related quality of life at 1\u00a0year in Canadian psoriasis patients in a real world setting. In:AAD Annual Meeting. Washington DC. March 1\u20105 2019; Poster #8375."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.031"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1622678"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.048"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17351"},{"key":"e_1_2_6_42_1","unstructured":"ReichK ArenbergerP MrowietzUet\u00a0al.Secukinumab Shows High and Sustained Efficacy in Nail Psoriasis: 2.5\u2010Year Results From the TRANSFIGURE Study. In:Psoriasis From Gene to Clinic 8th International Congress. London UK.2017."},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.058"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.910"},{"key":"e_1_2_6_45_1","unstructured":"AliceB GottliebJS AlexK RuquanY PascalineR JenniferF.Secukinumab Shows High and Sustained Efficacy in Subjects with Moderate to Severe Palmoplantar Psoriasis: 2.5\u2010Year Results from the GESTURE Study. In:Psoriasis From Gene to Clinic 8th International Congress. London UK.2017."},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.033"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23111"},{"key":"e_1_2_6_49_1","doi-asserted-by":"crossref","unstructured":"MeasePJ ReimoldA TahirHet\u00a0al.Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5\u2010year Efficacy and Safety Results from a Phase 3 Trial. In:ACR\/ARHP (2018) American College of Rheumatology\/ARHP \u2010 2018 Annual Scientific Meeting.2018.","DOI":"10.1136\/annrheumdis-2019-eular.2768"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23537"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160275"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"e_1_2_6_53_1","first-page":"656","article-title":"FRI0450 Commonalities and differences in data collection across European spondyloarthritis registries","volume":"76","author":"Hetland M","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_54_1","first-page":"1281","article-title":"SAT0391 remission and drug retention rates of secukinumab in 1549 patients with psoriatic arthritis treated in routine care \u2013 pooled data from the observational Eurospa research collaboration network","volume":"78","author":"Michelsen B","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.93"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209730"},{"key":"e_1_2_6_57_1","first-page":"50","article-title":"Long\u2010term effects of interleukin\u201017A inhibition with secukinumab in active ankylosing spondylitis: 3\u2010year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos X","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_6_59_1","unstructured":"BaraliakosX DeodharAA PoddubnyyDet\u00a0al.Long\u2010Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial. In:2018 ACR\/ARHP Annual Meeting: Arthritis Rheumatol. 2018; 70 (suppl 10).2018."},{"key":"e_1_2_6_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0598-8"},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39805"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000592"},{"key":"e_1_2_6_63_1","first-page":"888","article-title":"FRI0404 Pooled 6\u2010month treatment outcomes and drug retention rates in 1556 patients with axial spondyloarthritis treated with secukinumab in routine clinical practice in 12 European countries in the Eurospa research collaboration","volume":"78","author":"Michelsen B","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14096"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0770"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.03031.x"},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.02.015"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12487"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0619-z"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-013-1354-5"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.04.012"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01325.x"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939473"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059531"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2016.01.010"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13227"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.03.024"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2800"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100123"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0749"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxp025"},{"key":"e_1_2_6_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.477"},{"key":"e_1_2_6_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.025"},{"key":"e_1_2_6_86_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202371"},{"key":"e_1_2_6_87_1","first-page":"369","article-title":"Invariant NKT cells produce IL\u201017 through IL\u201023\u2010dependent and \u2010independent pathways with potential modulation of Th17 response in collagen\u2010induced arthritis","volume":"22","author":"Yoshiga Y","year":"2008","journal-title":"Int J Mol Med"},{"key":"e_1_2_6_88_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300274"},{"key":"e_1_2_6_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206323"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.205"},{"key":"e_1_2_6_91_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3370"},{"key":"e_1_2_6_92_1","doi-asserted-by":"publisher","DOI":"10.1159\/000316171"},{"key":"e_1_2_6_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03363.x"},{"key":"e_1_2_6_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12272"},{"key":"e_1_2_6_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24172"},{"key":"e_1_2_6_96_1","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2017.68912"},{"key":"e_1_2_6_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.10.042"},{"key":"e_1_2_6_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1601014"},{"key":"e_1_2_6_99_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220868"},{"key":"e_1_2_6_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_2_6_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_6_102_1","first-page":"83","article-title":"Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date","volume":"8","author":"Machado A","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"e_1_2_6_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_2_6_104_1","unstructured":"New Phase 3 data demonstrate superiority of TREMFYA\u00ae (guselkumab) vs Cosentyx\u00ae (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48. In.Content Lab \u2010 US n.d.[cited 2019 Feb 10]; Available from:https:\/\/www.jnj.com\/new-phase-3-data-demonstrate-superiority-of-tremfya-guselkumab-vs-cosentyx-secukinumab-in-delivering-pasi-90-responses-in-the-treatment-of-moderate-to-severe-plaque-psoriasis-at-week-48."},{"key":"e_1_2_6_105_1","unstructured":"A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate\u2010to\u2010Severe Plaque Psoriasis (IXORA\u2010R). In:ClinicalTrials.gov Identifier: NCT03573323."},{"key":"e_1_2_6_106_1","unstructured":"Lilly Announces Superiority of Taltz\u00ae(ixekizumab) versus TREMFYA\u00ae(guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head\u2010to\u2010Head (IXORA\u2010R) Trial in People Living with Moderate to Severe Plaque Psoriasis. In: Published: Aug 13 2019"},{"key":"e_1_2_6_107_1","unstructured":"Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis. ClinicalTrials.gov Identifier: NCT03478787."},{"key":"e_1_2_6_108_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0075"},{"key":"e_1_2_6_109_1","unstructured":"Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis (EXCEED 1). ClinicalTrials.gov Identifier: NCT02745080."},{"key":"e_1_2_6_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41042"},{"key":"e_1_2_6_111_1","unstructured":"Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) (SURPASS). ClinicalTrials.gov Identifier: NCT03259074."},{"key":"e_1_2_6_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0294-7"},{"key":"e_1_2_6_113_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1551-x"},{"key":"e_1_2_6_114_1","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double\u2010blind, phase III FUTURE 5 study","volume":"77","author":"Mease PJ","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23233"},{"key":"e_1_2_6_116_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1490-y"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T16:25:48Z","timestamp":1693758348000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":115,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1111\/jdv.16124"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16124","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,7]]},"assertion":[{"value":"2019-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}